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1. Introduction 
Radiation therapy alone or in combination with chemotherapy has lead to improved 
outcomes in the management of rectal cancer patients. Many studies have demonstrated 
that for locally advanced rectal cancer, preoperative chemoradiation (CRT) significantly 
improves local control, reduces toxicity profiles and the risk of disease recurrence (Habr-
Gama, Perez et al. 2004), (Kapiteijn, Marijnen et al. 2001), (Frileux, Burdy et al. 2007), 
(Horisberger, Hofheinz et al. 2008), (Krook, Moertel et al. 1991), (Sauer, Becker et al. 2004). 
Highly radiosensitive cancers completely regress, leading to improved survival. A histology 
tumor grading system is used to determine the success of radiation prior to surgery. This is 
called a tumor regression grade (TRG). Originally described for oesophageal tumors, the 
TRG system has been adapted to rectal cancer (Mandard, Dalibard et al. 1994). Regression 
grading stratifies response based on the biological effect of radiation on tumors, dividing it 
into five different grades based on the ratio of fibrosis to tumor where TRG1: no residual 
cancer; TRG2: rare residual cancer cells; TRG3 fibrosis outgrowing residual cancer; TRG4: 
residual cancer outgrowing fibrosis and TRG 5: absence of regressive changes. This TRG 
scoring system is extremely valuable as it can highlight those tumors demonstrating large 
variation in biological response to radiation not undergoing a T stage change (Bouzourene, 
Bosman et al. 2002). In a paper by Ryan et al, they have revised the 5 point TRG system into 
a 3 point where grade 1 indicates a complete response, grade 2 a partial response and grade 
3 no response (Ryan, Gibbons et al. 2005). Currently, only approximately 25% of patients 
who receive CRT treatment obtain a complete pathological response (Valentini, Coco et al. 
2002; Sauer, Becker et al. 2004). Disease free survival in these patients is improved with a 
reduce rate of local recurrence However, up to 75% of patients receive a treatment that 
achieves little or no benefit and an increased risk of second cancers has been documented 
within or adjacent to the irradiated volume (Birgisson, Pahlman et al. 2005).  
The broad and unpredictable response to tumor of patients with rectal cancer treated with 
preoperative chemoradiotherapeutic interventions shows that our understanding of the 
molecular events leading to radioresistance in patients affected with this malignancy is 
limited. This variation is thought to depend on tumor size but also on the biological 
properties of individual tumors. It is important to understand what factors within the tumor 
predict high sensitivity to the new-adjuvant regimen and what determines resistance, as this 
information may allow tailor-made individualization of therapy. Classification of 
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responders and non responders may also spare poorly responding patients from 
undergoing treatment which would derive no benefit for them. In contrast, the ability to 
predict good response may alter the subsequent management of patients. Many studies 
have examined prognostic and predictive molecular marker expressions in rectal cancer 
treated with neo-adjuvant radio-chemotherapy.  However, some of these studies only 
examined expression profiles in the tumor excised after surgery (Bertolini, Bengala et al. 
2007). In this chapter, we will critically review the assessed predictors of histological 
response to new-adjuvant radiation for rectal cancer patients. There are many studies in the 
literature which have compared biomarker expression levels before and after new-adjuvant 
treatment and correlated expression differences with a measure of patient outcome. These 
studies however are not as useful in prospectively predicting which patients will respond to 
new-adjuvant therapy and are not discussed in this review. 
Studies utilizing molecular response predictors from archival pre-treatment tumor tissues 
have identified several promising predictive markers including p21, thymidylate synthase 
expression, EFGF status, apoptosis markers and p53 gene status. Global gene expression 
studies have also been performed. We will discuss these and others in relation to their 
ability to predict response and resistance to new-adjuvant treatment for rectal cancer 
patients. A number of listed biomarkers above will be discussed in detail in relation to their 
potential to predict response. A number of these factors can interact together at different 
cellular levels (Figure 1).  
In figure 1, p53 can induce apoptosis, growth arrest and or senescence. Activation of p53 can 
induce expression or activation of pro-apoptotic Bcl2 family proteins (eg: Bax, Puma and 
Noxa) that coverge on the mitochondria and induce cytochrome c release. In the cytosol, 
cytochrome c binds Apaf1 which activates caspase 9 which activates caspase 3. It is also 
proposed that p53 can impair mitochondrial function. The p53 mediated mitochondrial 
dysfunction triggers a cycle of DNA damage, p53 activation, a compromised mitochondria 
and increased ROS levels leading to additional DNA damage.  
2. Biomarker analyses 
2.1 p21 
The p21 protein is transcriptionally activated by p53 in response to DNA damage (el-Deiry, 
Kern et al. 1992). This causes the cells to arrest in G1 through the alteration of cyclin 
dependent kinases. It has been studied as a response predictor as disruption of the cell cycle 
networks may be a causative factor of radioresistance (Waldman, Kinzler et al. 1995), 
(Brugarolas, Chandrasekaran et al. 1995). Loss of wild type p21 or the presence of mutated 
p21 can radiosensitise cancer cells (Lu, Yamagishi et al. 1998), (Waldman, Lengauer et al. 
1996), (Wang, Elson et al. 1997), (Tian and Quaroni 1999). On the basis of in vitro studies, it 
is predicted that tumors with low or absent p21 expression would be more sensitive to 
radio/and chemotherapy, ultimately leading to improved patient outcome. The levels of 
p21 expression have been investigated in a small number of immunohistochemistry based 
studies, some of which demonstrated some association with response (Reerink, Karrenbeld 
et al. 2004), (Fu, Tominaga et al. 1998; Qiu, Sirivongs et al. 2000). Some of these studies 
showed that positive p21 tumors were associated with poor survival (Reerink, Karrenbeld et 
al. 2004; Bertolini, Bengala et al. 2007). Four year overall survival rates in biopsies with high 
p21 expression levels was 43% compared with 83% 4 year survival in biopsies with low p21 
expression levels (Bertolini, Bengala et al. 2007). However, others have shown no correlation 
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between p21 expression levels and pathologic response (Rau, Sturm et al. 2003). The 
inclusion of p21 screening is warranted, as the referenced studies in table 1 below had low 
case numbers and results between centers did not show good reproducibility.  
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Fig. 1. p53 interaction with p21, DNA repair and mitochondrial dysfunction 
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Low p21 correlates with improved survival
Author Technique Study Outcome
Bertolini et al
Rau et al
Reerink et al
Kudrimoti et al
Charara et al
Negri et al
Lin et al
Chang  et al
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
Low p21 correlates with non responders
P21 positive tumors detected in responders
High p21 correlates with poor survival
No correlation
No correlation
No correlation
No correlation
 
Table 1. Studies assessing p21 and Patient Outcome 
2.2 Thymidylate synthase 
Thymidylate synthase (TS) plays a crucial role in DNA synthesis. It is a primary target of 5-
fluorouracil (5-FU) in the treatment of colorectal cancer. Overexpression of TS is associated 
with 5FU resistance and overall poor patient outcome (Salonga, Danenberg et al. 2000), 
(Lenz, Danenberg et al. 1998). Numerous studies assessing TS expression have found that 
pretreatment biopsies negative for TS were predictive of response (Saw, Morgan et al. 2003), 
(Diez, Ramos et al. 2003), (Jakob, Liersch et al. 2008), (Negri, Campanini et al. 2008). 3 
studies revealed a better outcome with low or absent pretreatment TYMS expression, 
however another study demonstrated better outcome with high TYMS expression. It must 
be noted that the studies that did show a strong correlation between high pretreatment 
TYMS and outcome were performed on very small patient numbers. Therefore, the use of 
TYMS IHC screening is not recommended based on these small pilot studies performed. 
Evaluation of the TYMS allele has also been examined which determines the number of 
tandem repeats in the TYMS gene promoter region (Spindler, Nielsen et al. 2007), (Horie, 
Aiba et al. 1995), (Kawakami, Salonga et al. 2001) (44, 52,53). Villafranca et al has shown that 
patients homozygous for the triple repeat showed 22% downstaging compared to 60% 
downstaging in patients either homozygous for the double repeat (Horie, Aiba et al. 1995). 
TYMS DNA analyses may be valuable as a predictive biomarker, however its clinical utility 
needs to be evaluated in larger multi-center studies. 
2.3 P53  
P53 is known to play a role in apoptosis and in regulating sensitivity of tumors to radiation 
and chemotherapy (Bunz, Hwang et al. 1999), (Bunz, Dutriaux et al. 1998), (Kuerbitz, 
Plunkett et al. 1992), (Lowe, Schmitt et al. 1993), (Lowe, Ruley et al. 1993). For this reason, 
p53 is the most studied response predictor in rectal cancer with to date 22 different studies 
examining its potential to predict response to new-adjuvant treatment for rectal cancer 
patients. Assessment of p53 status has been performed by many different techniques 
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including immunohistochemistry, polymorphism screening and direct gene sequencing 
(Reerink, Karrenbeld et al. 2004), (Rebischung, Gerard et al. 2002), (Kandioler, Zwrtek et al. 
2002), (Qiu, Sirivongs et al. 2000), (Fu, Tominaga et al. 1998), (Rodel, Grabenbauer et al. 
2002), (Abe, Sakaguchi et al. 2001), (Sakakura, Koide et al. 1998), (Luna-Perez, Arriola et al. 
1998), (Komuro, Watanabe et al. 2003), (Spitz, Giacco et al. 1997), (Elsaleh, Robbins et al. 
2000), (Saw, Morgan et al. 2003), (Scott, Hale et al. 1998), (Okonkwo, Musunuri et al. 2001), 
(Tannapfel, Nusslein et al. 1998), (Kim, Park et al. 2001), (Spitz, Giacco et al. 1997). The 
majority of work has been IHC based studies. Of these, only 18% of studies could be used to 
significantly predict response (Fu, Tominaga et al. 1998), (Spitz, Giacco et al. 1997; Komuro, 
Watanabe et al. 2003). These showed that pretreatment biopsies negative for p53 were 
predictive of complete tumor regression. The remaining 82% of studies did not show a 
positive association with levels of p53 expresison and treatment response. Some of the 
biggest studies were performed by Chang et al, and Bertolini et al and these revealed no 
correlation between mutant p53 expression and treatment outcome (Chang, Jung et al. 2005), 
(Bertolini, Bengala et al. 2007). Direct sequencing of the p53 gene (exons 2-10) revealed 
mutant p53 genotype was significantly associated with radioresistance (Rebischung, Gerard 
et al. 2002), (Kandioler, Zwrtek et al. 2002). These 2 studies revealed similar results however, 
the number of independent groups validating these results are limited. Overall, the majority 
of studies revealed no correlation between p53 and treatment outcome, suggesting that p53 
is unlikely to serve as a predictor of response to new-adjuvant CRT.  
 
 
Author Technique Study Outcome
Negri et al
Saw et al
Okonkuro et al
Jakob et al
Bertolini et al
Stoehlmacher et al
Spindler et al
Willafranca et al
Terrazzino et al
IHC
IHC
IHC
IHC
PCR
PCR
PCR
PCR
PCR
High TYMS correlates with high rate of response
Lack of TYMS correlates with T stage downstaging
No correlation
No correlation
Low TYMS correlates with increased TRG stage
Non significant
TYMS2/2 levels correlate with increased TRG stage
TYMS2/2 levels correlate with increased TRG stage
TYMS2/2 levels correlate with increased TRG stage
 
 
Table 2. Studies assessing Thymidylate Synthese and Patient Outcome 
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Author Technique Study Outcome
Jakob et al
Kim et al
Scott et al
Kudnmoti et al
Okonkuo et al
Luna Perez et al
Reerink et al
Terzi et al
Esposito et al
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
IHC
No correlation
No correlation
No correlation
No correlation
No correlation
No correlation
Positive p53 correlated with more tumor regression
Positive p53 correlated with less tumor regression
No correlation
Spitz et al
Rodel et al
Rau et al
Lin et al
Chang et al
Diez et al
Terrazzino et al
IHC
IHC
IHC
IHC
IHC
IHC
No correlation
Positive p53 correlated with less tumor regression
No correlation
Negative p53 correlated with higher rate of response
No correlation
No correlation
Bertolini et al IHC No correlation
IHC No correlation
 
Table 3. Studies assessing p53 and Patient Outcome 
2.4 Epidermal growth factor receptor (EGFR) 
EGFR regulates many different cellular processes including cell proliferation, differentiation 
and apoptosis. It is overexpressed in 50-70% of cancers and is associated with more 
advanced tumor staging, poor prognosis and radiation resistance. (Akimoto, Hunter et al. 
1999), (Liang, Ang et al. 2003). It has also  been used as a therapeutic target with the 
development of new molecular targeted therapies such as Cetuximab (Eribitux) (You and 
Chen), (Liu, Guo et al.), (Liao, Sun et al.). There is very limited evidence on this receptor in 
relation to response to radiation in rectal cancer patients (Giralt, de las Heras et al. 2005), (Li, 
Kim et al. 2006), (Spindler, Nielsen et al. 2006), (Spindler, Nielsen et al. 2007). One study has 
shown an association between high EGFR levels and poor survival (Liu, Guo et al.). In 
tumors showing more than 50% positivity correlated with a shorter disease free survival. 
Multivariate analysis demonstrated low EGFR expression was a predictive factor for tumor 
downstaging (Liu, Guo et al.). The debate for screening EGFR levels is very weak and 
tenuous.  
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Author Technique Study Outcome
Spindler et al
Spindler et al
Bertolini et al
Kim et al
Giralt et al
IHC
PCR
IHC
IHC
No correlation
EGFA61G SNP + EGFRSp1 with TYMS2/2 predicts
Increased tumor regression
No correlation
No correlationIHC
No correlation
 
Table 4. Studies assessing EGFR and Patient Outcome 
2.5 Ki67 and Cox2 
Ki67 is required for cell cycle control (Scholzen and Gerdes 2000), (Schluter, Duchrow et al. 
1993), (Linden, Ma et al. 1993). While it has been used as a prognostic factor for colorectal 
cancer, results have been inconclusive (Ogata, Greca et al.), (Guzinska-Ustymowicz, 
Pryczynicz et al. 2009), (Santagostino, Saggia et al. 2007). A small number of independent 
studies have examined the levels of Ki67 positivity in pretreatment biopsies from rectal 
cancer patients (Kudrimoti, Lee et al. 2007), (Debucquoy, Goethals et al. 2006), (Tannapfel, 
Nusslein et al. 1998), (Reerink, Karrenbeld et al. 2004), (Rodel, Grabenbauer et al. 2002), 
(Charara, Edmonston et al. 2004), Some studies have shown a positive association with Ki67 
index higher in responders compared to non responders (Kim, Park et al. 2001; Jakob, 
Liersch et al. 2008). The remaining studies showed no correlation between Ki67 status and 
patient outcome. In the small number of studies that did show a positive correlation 
between Ki67 and response, these were conducted on a very small patient cohort. It appears 
unlikely that measurement of the proliferation status in pretreatment biopsies will be 
clinically useful.  
Another molecule known to promote tumor growth is Cox 2. Cox 2 catalyses the conversion 
of arachidonic acid to protaglandins, especially PGE2. COX2 inhibition in conjunction with 
radiation can significantly enhance tumor response by blocking prostaglandin release (Kishi, 
Petersen et al. 2000).  In laryngeal (Nix, Lind et al. 2004) and cervical cancers (Kim, Kim et al. 
2004), (Kim, Kim et al. 2002), COX 2 expression in pre treatment biopsies may be indicative 
of treatment response to CRT. Cox2 has been evaluated in pre rectal biopsies (Watwe, Javle 
et al. 2005), (Kobayashi, Hashiguchi et al. 2007), (de Heer, Gosens et al. 2007), (Giralt, 
Navalpotro et al. 2006), (Min, Choi et al. 2008), (Smith, Reynolds et al. 2006). And its 
overexpression was significantly associated with poor response to treatment, suggesting 
that COX2 may mediate radioresponsiveness. However, study numbers are small and no 
multi-centre studies to validate these findings have been reported to date.  
2.6 Mitochondrial proteins bcl2/bax 
Bcl2 and Bax regulate caspase activation and this activation can regulate apoptosis in many 
disease states (Teijido and Dejean), (Thees, Hubbard et al. 2005), (Brambilla, Negoescu et al. 
1996). Bcl2 and Bax are prosurvival and proapoptotic proteins respectively. Bcl2 maintains 
mitochondrial outer membrane integrity (Teijido and Dejean ; Luo, Budihardjo et al. 1998; 
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Zhang, Holzgreve et al. 2001). Bax can be activated by pro apoptotic stimuli or p53 and 
expression can be altered following radiation and is associated with resistance to 
chemotherapy (Miguel, Wajsenzon et al. 2007), (Przemeck, Duckworth et al. 2007), (Murphy, 
Mabruk et al. 2002), (Johnson, Xiang et al. 1998; Butt, Firth et al. 2000), (Strobel, Swanson et 
al. 1997), (Khanna, Wie et al. 1996). This is in contrast to overexpression of bcl2 is associated 
with chemotherapy resistance and protects cells from radiation induced apoptosis (Hahn, 
Lai et al. 2003), (Vrana, Grant et al. 1999). 12 studies have assessed these proteins, 8 for Bcl2 
expression and 4 have evaluated Bax expression as predictive markers (Qiu, Sirivongs et al. 
2000), (Rodel, Grabenbauer et al. 2002), (Rodel, Hoffmann et al. 2002), (Scott, Hale et al. 
1998), (Okonkwo, Musunuri et al. 2001). Only one study has found that Bcl2 was an 
indicator of response in pre treatment biopsies, where 60% of complete responders were 
bcl2 positive in pretreatment biopsies compared to 16% bcl2 positive in the partial 
responders. One of the  Bax studies showed a significant correlation between higher Bax 
expression in biopsies associated with treatment response. Overall, these markers do not 
prove useful as significant markers of response to new-adjuvant CRT. 
 
Author Technique Study Outcome
Kudrimoti et al
Chang et al
Okonkwo et al 
Reerink et al
Scott et al
Tannapfel et al
Charara et al
Rodel et al
IHC
IHC
IHC
IHC
PCR
IHC
IHC
IHC
Positive bcl2 expression correlates with complete
response
Bax expression correlates with increases tumor
regression
No correlation
No correlation
No correlation
No correlation
No correlation
No correlation
 
Table 5. Studies assessing bcl2/bax and Patient Outcome 
2.7 Microsatellite instability, mis match repair and hypoxia  
Evaluation of the levels of DNA repair in pretreatment biopsies may be important in 
predicting response or resistance to CRT. Tumors which show microsatellite instability 
usually have a better prognosis and have altered response to radiotherapy compared to 
tumors with an intact repair system (Peltomaki 2003). This effect has been evaluated in a 
small number of clinical trials, however screening for MSI status and presence or absence of 
the mis match repair proteins did not correlation with treatment response (Qiu, Sirivongs et 
al. 2000), (Charara, Edmonston et al. 2004), (Rau, Sturm et al. 2003) . However, assessment of 
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Ku70, a protein involved in double strand break repairs (Ayene, Ford et al. 2005) could 
predict response when combined mutant p53 status (Komuro, Watanabe et al. 2003). 
Markers of tumor hypoxia have also been assessed as a response predictor in rectal cancer. 
Qui et al have found that histological response was not correlated to VEGF expression levels 
in pretreatment biopsies (Qiu, Sirivongs et al. 2000). Other studies combined VEGF 
expression levels in serum/plasma with serial dynamic contrast-enhanced (DCE) MRI, a 
marker of vessel permeability. While again VEGF levels did not correlate with treatment 
response, higher permeability on DCE MRI significantly correlated with better response to 
CRT (George, Dzik-Jurasz et al. 2001).  
2.8 Microarray and proteomic studies 
While targeted-therapies use single marker approaches, tumor response to CRT is complex 
and unlikely to be attributed to one factor alone. Transcriptional profiling of tumors has 
shown considerable promise as a predictive approach to treatment, with commercially 
available microarray profiling platforms, MammaPrint and OncoTypeDX, already in place 
for breast cancer prognostics (van 't Veer, Dai et al. 2002; Paik, Shak et al. 2004). This has 
provided support for predictive genomics research in other cancer types, including rectal 
cancer. A number of studies carried out in recent years have aimed to identify gene and/or 
protein signatures predictive of response to CRT in rectal cancer. Prior to the development 
of genomic and proteomic screening studies, assessment of predictive markers suggested 
that p53, Bcl2, Bax, and microsatellite instability are of no predictive value as discussed 
above.  
Ghadimi et al. were among the first to use gene expression profiling with the aim of 
predicting response to new-adjuvant CRT in rectal cancer (Ghadimi, Grade et al. 2005). A 
significant difference in gene expression was identified between responders and non-
responders for 54 genes, while the ability of this gene profile to predict response was 
validated in 83% of patients (78% sensitivity, 86% specificity). While this is a promising 
observation, the authors noted that validation of these findings in large, independent 
studies would be required. Watanabe et al. also carried out DNA microarray analysis of 
gene expression profiles in response to new-adjuvant radiotherapy in rectal cancer 
(Watanabe, Komuro et al. 2006). They identified 33 genes with a significant difference in 
expression between responders and non-responders (82.4% accuracy).  
While expression of pro-apoptotic genes was higher in responders, anti-apoptotic gene 
expression was higher in non-responders. A later study carried out gene microarray analysis 
on tumor tissues from 46 patients with rectal cancer, with response to CRT evaluated using 
Dworaks tumor regression grade. From a gene-set comprising the top-ranked 95 genes 
demonstrating altered expression (between partial and complete-response), response to CRT 
was accurately predicted in 84% of training samples and 87% of validation samples (Kim, 
Lim et al. 2007). Using 43 biopsy specimens from patients with locally advanced rectal 
adenocarcinoma, a 43-gene expression signature of response was identified by Rimkus et al 
(Rimkus, Friederichs et al. 2008). These genes mainly encoded proteins involved in nuclear 
processes, associated with transport function, or implicated in apoptosis regulation 
(caspase-1), supporting previous observations (Watanabe, Komuro et al. 2006). A 
subsequent small study of rectal cancer patients who underwent preoperative CRT (n=17) 
revealed seventeen genes with significantly altered gene expression levels. These included 
apoptosis, metalloproteinase, transforming growth factor beta-1, DNA repair, and cell 
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proliferation-related genes (Nishioka, Shimada et al.). The activity of certain subsets of 
kinase signaling pathways has also been proposed to predict response to CRT in rectal 
cancer. A microarray study of 67 patients with advanced stage rectal cancer suggested that 
multiplex kinase activity profiling may identify biomarkers to predict tumor response to 
CRT, with several discriminating phosphosubstrates representing proteins derived from 
signaling pathways implicated in radioresistance (Folkvord, Flatmark et al.). 
Using a panel of 48 cancer cell lines, a 10-gene signature of radiosensitivity was identified 
and used as a predictor of an intrinsic radiosensitivity index (RSI). This was applied to a 
rectal cancer cohort, which was treated with concurrent chemoradiation. The predicted RSI 
was significantly different in responders versus non-responders. This effect was also 
observed in head-and-neck and oesophageal cancer cohorts, a combined total of 118 patients 
and the first systems-based radiosensitivity model to be validated in multiple datasets 
(Eschrich, Pramana et al. 2009). A subsequent study used 12 colorectal cancer cell lines to 
examine response to CRT. The authors identified many genes involved in the MAP-kinase 
pathway or cell cycle genes, and suggested that both insulin and Wnt signaling pathways 
may have relevance for treatment response.  
A recent study was carried out to examine expression profiles from pretreatment biopsies 
for 51 rectal cancer patients. However, the classifiers obtained from this study did not have 
high sensitivity/specificity, with those with highest sensitivity having poor specificity and 
vice versa. Validation of these classifiers with previously published data was also difficult, 
prompting the authors to suggest that microarray analysis is not a valuable tool for 
predictive studies in rectal cancer (Brettingham-Moore, Duong et al.). Alternatives 
approaches should therefore also be considered for future predictive studies in rectal cancer. 
 
Author Technique Study Outcome
Ghadimi et al
Watanabe et al
Okonkwo et al 
Allal et al
Kim et al
DNA Microarray
DNA Microarray
DNA Microarray
Proteomics
54 gene panel predicts response
(78% sensitivity and 86% specificity
95 gene signature predicts response
(87% validation)
Differential expression of proteins between
responders and non responders.
Protein targets:
Tropomodulin, heat shock 42, keratin 1 
and notch2
33 gene panel predicts response
(82% accuracy)
 
Table 6. Studies assessing array profiles and patient outcome 
A small number of studies have used proteomic approaches to identify a protein signature 
which can predict response to CRT. The earliest of these used 2D genes and subsequent 
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mass spectrometry to identify a small number of proteins which correlated with treatment 
response. These included tropomodulin, heat shock protein 42, keratin type 1 and notch-2 
protein homolog. A number of these proteins are known to be associated with 
radioresistance (Allal, Kahne et al. 2004). The use of an integrated microarray and 
proteomics approach to predict response of patients on cetuximab demonstrated an 
enhanced predictive power, with 5 genes and 10 proteins predicting rectal cancer regression 
grade with 91.7% accuracy, 96.2% sensitivity and 80% specificity (Daemen, Gevaert et al. 
2008). A similar approach was later taken by Debucquay et al., who found that 16 genes 
were significantly altered following microarray analysis (Debucquoy, Haustermans et al. 
2009). A decrease in proliferation gene expression was confirmed by IHC for Ki67 and 
further supported by an increase in TGFα in plasma samples from rectal cancer patients. 
3. Concluding remarks 
The relationship between biomarker expression and histological response to CRT has been 
investigated in a large number of studies. The vast majority of these studies have assessed 
single or multiple pre defined markers in small cohorts of patients. However, through these 
studies, a limited number of promising markers have been identified including TS 
expression, increased p21 and EGFR expression levels. While these markers have been 
assessed and have shown some promise, due to the limited number of studies assessing 
each marker using the same protocol, no marker to date can be considered as a clinical 
biomarker. The biggest problem with the studies has been the lack of statistical power. 
Assessment of these markers should be prospectively evaluated to elucidate their role as 
measures of predictive outcome, however it is unlikely that any single factor will determine 
response so a more global approach maybe more advantageous. The development of novel 
therapeutic targets for rectal cancer maybe greatly aided by the generation of global gene 
and protein expression profiles for responders and non-responders through microarray and 
proteomic studies. However, this will only be made possible by the use of large cross-
institutional studies.  
The discovery of specific biomarkers that could potentially predict a tumor response to 
treatment could prevent the above mentioned unfavorable consequence while focusing on 
patients that will benefit from new-adjuvant treatment. A successful biomarker(s) should 
predict responders versus non responders with high sensitivity and specificity levels. This 
biomarker should be validated prospectively in different patient cohorts from multi centre 
hospitals. Importantly, to conduct these prospective studies, it is vital that there is limited 
variation in the dose and duration of radiation, inclusion or type of chemotherapy given and 
pathological endpoints assessed. Another caveat is in relation to the collection and analysis. 
It is unknown whether the endoscopy biopsy truly reflects the biology of the tumor as a 
whole. Also, variability in IHC scoring systems could alter study outcomes. To date, these 
issues may contribute to conflicting results for the potential biomarkers as discussed in this 
chapter. In conclusion, the response of rectal adenocarcinoma to neo-adjuvant chemo-
radiotherapy is limited to a defined group of patients. It is hoped in the future that the 
therapeutic course will be tailored to each patient based on analyses of initial pre treatment 
biopsy assessment, thus minimizing unnecessary treatment for rectal cancer patients. The 
next investigative step would be to conduct, initially, phase II trials prospectively to validate 
the predictive power of the most promising predictive markers and eventually phase III 
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prospective trials to separate categories of patients based on the likelihood of tumor 
response according to expression of the different molecules. 
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